Immunohistochemical analysis revealed reduced expression levels of CD31+ MVD in the tumor tissues of either CPZ‐treated, sorafenib‐treated, or combined‐treated groups, indicating inhibition of tumor angiogenic pathways (Figure 6D). Here, PECAM1 is linked to neoplasm.